Precision BioSciences
![](../Images/upgraded1Icon.png)
Precision BioSciences is dedicated to improving life (DTIL) through the application of its pioneering, proprietary genome editing platform, ARCUS. Precision leverages ARCUS to develop product candidates in allogeneic (off-the-shelf) CAR T immunotherapy, in vivo gene correction, and food. Its lead clinical programs are currently in the allogeneic CAR T space with the most advanced product candidate being PBCAR0191, an allogeneic anti-CD19 CAR T therapy candidate currently being evaluated in collaboration with Servier in adult patients with relapsed or refractory NHL or B-ALL. Precision initiated dosing of subjects in a Phase 1/2a clinical trial of PBCAR0191 in April 2019, which continues to progress as planned. In September 2019, Precision announced FDA clearance of its IND for PBCAR20A, the company’s second and wholly-owned allogeneic CAR T candidate targeting CD20. Precision expects to file an IND for its wholly-owned BCMA targeted allogeneic CAR T candidate in 2020.